Diaprost announced today that it has signed an exclusive license agreement with Memorial Sloan Kettering Cancer Center for IP related to the use of PSA antibodies for therapeutic and diagnostic purposes for prostate cancer.
Diaprost announces Exercise of Option under the terms of its Research and Option Agreement with a leading Pharmaceutical company
Diaprost entered into an exclusive Research and Option Agreement with a Top 10 Pharmaceutical company strategic partner in October 2017. Diaprost now announces that its strategic partner has exercised its option to acquire rights to its h11B6 antibody.
Diaprost have agreed terms for an exclusive Research and Option Agreement, inclusive of an upfront payment, research funding and potential development milestone payments for its h11B6 antibody for prostate cancer.
Study demonstrates the feasibility of targeting human kallikrein-related peptidase 2 (hK2) for detection and monitoring of prostate cancer
A new publication in Science Translational Medicine demonstrates that in vivo targeting of the enzyme human kallikrein-related peptidase 2 (hK2) is a powerful tool that can be used for detection of prostate cancer and monitoring treatment by quantifying the activity of the androgen receptor pathway.